Phase 2, Multicenter Randomized, Double-Blind, Placebo-Controlled, Safety and Efficacy Study Evaluating a Single Dose of Intravenous NA-1 in Patients With Subarachnoid Hemorrhage Undergoing Endovascular Repair of Ruptured Intracranial Aneurysms

Trial Profile

Phase 2, Multicenter Randomized, Double-Blind, Placebo-Controlled, Safety and Efficacy Study Evaluating a Single Dose of Intravenous NA-1 in Patients With Subarachnoid Hemorrhage Undergoing Endovascular Repair of Ruptured Intracranial Aneurysms

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 06 Aug 2015

At a glance

  • Drugs NA 1 (Primary)
  • Indications Intracranial aneurysm; Subarachnoid haemorrhage
  • Focus Therapeutic Use
  • Acronyms ENACT-2
  • Sponsors NoNO
  • Most Recent Events

    • 03 Aug 2015 Status changed from not yet recruiting to withdrawn prior to enrolment as per ClinicalTrials.gov record.
    • 31 Mar 2015 Planned End Date changed from 1 Apr 2019 to 1 Apr 2020, according to to ClinicalTrials.gov record.
    • 31 Mar 2015 Planned primary completion date changed from 1 Nov 2018 to 1 Nov 2019, according to to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top